Addressing Unmet Medical Needs in HCV Genotype 3

A CASE-BASED APPROACH

Saturday April 18, 2015  ♦  07:15 – 08:45 (Registration and Breakfast: 07:15 – 07:45)
Tupper Room – PEI Convention Centre  ♦  NOTE: Maximum of 50 participants (registration required)

Learning Objectives

Following their participation in this program, participants will be able to:
• Identify treatment options available to various HCV patient populations
• Cite efficacy, safety, and tolerability data of different therapeutic options
• Recognize the expanding treatment armamentarium of HCV

Agenda

07:15 - 07:45  Registration and Breakfast
07:45 - 07:50  Opening Remarks  Dr. Duncan Webster
07:50 - 08:35  Presentation  Dr. Karen Doucette
08:35 - 08:45  Question and Answer, Discussion, and Closing Remarks  Dr. Duncan Webster

Moderator
Duncan Webster, BSc, BA, MA, MD, FRCPC
Internist,
Infectious Disease Physician, Department of Medicine
Medical Microbiologist,
Department of Laboratory Medicine, Saint John Regional Hospital
Associate Professor,
Dalhousie University, Faculty of Medicine
Memorial University, Faculty of Medicine

Speaker
Karen Doucette, MD, MSc (Epi), FRCPC
Associate Professor,
Division of Infectious Diseases, Department of Medicine
University of Alberta

Click Here to Register: http://fluidsurveys.com/s/2015WorkshopBMS/

This presentation will focus on new treatments available to genotype 3 treatment-naïve patients as well as difficult-to-treat patients (including those post-transplant). Using a case-based approach, our faculty will highlight the challenges specific to these patient types and discuss the optimal treatment options available in this rapidly changing clinical environment.